Tilatamig Biosimilar – Anti-Tyrosine-protein kinase Met;ERBB1 mAb – Research Grade from ProteoGenix; catalogue PX-TA2218; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Tilatamig Biosimilar is a therapeutic antibody that targets the tyrosine-protein kinase Met and ERBB1, two important proteins involved in cancer development and progression. This biosimilar is a research-grade version of the original Tilatamig antibody, which has shown promising results in clinical trials for the treatment of various types of cancer. In this article, we will explore the structure, activity, and potential applications of Tilatamig Biosimilar.
Tilatamig Biosimilar is a monoclonal antibody, meaning it is produced from a single type of immune cell. It is a biosimilar, which means it is highly similar to the original Tilatamig antibody in terms of structure, function, and clinical efficacy. The structure of Tilatamig Biosimilar is composed of two heavy chains and two light chains, connected by disulfide bonds. These chains form a Y-shaped structure, with the two arms of the Y binding to the target proteins, Met and ERBB1.
Tilatamig Biosimilar exerts its activity by specifically binding to the tyrosine-protein kinase Met and ERBB1. These proteins are overexpressed in many types of cancer and play a critical role in cancer cell growth, survival, and metastasis. By binding to these proteins, Tilatamig Biosimilar blocks their activity and inhibits the growth and spread of cancer cells. This mechanism of action makes Tilatamig Biosimilar a promising therapeutic agent for the treatment of various types of cancer.
Tilatamig Biosimilar has shown promising results in preclinical and clinical studies for the treatment of different types of cancer, including lung, breast, and gastric cancer. It has been found to be effective in both inhibiting the growth of cancer cells and reducing tumor size. In addition, Tilatamig Biosimilar has also shown potential in combination therapies with other anti-cancer drugs, such as chemotherapy and targeted therapies.
Lung cancer is the leading cause of cancer-related deaths worldwide, and the overexpression of Met and ERBB1 has been linked to its development and progression. Tilatamig Biosimilar has shown promising results in preclinical studies for the treatment of non-small cell lung cancer (NSCLC), the most common type of lung cancer. It has been found to inhibit the growth and migration of NSCLC cells and reduce tumor size in animal models.
Breast cancer is the most commonly diagnosed cancer in women, and Met and ERBB1 have been implicated in its development and progression. Preclinical studies have shown that Tilatamig Biosimilar can inhibit the growth and metastasis of breast cancer cells, making it a potential therapeutic option for this disease.
Gastric cancer, also known as stomach cancer, is the fifth most common cancer worldwide. Studies have shown that Met and ERBB1 are overexpressed in gastric cancer and play a critical role in its development and progression. Tilatamig Biosimilar has been found to inhibit the growth and spread of gastric cancer cells, making it a potential treatment option for this disease.
In conclusion, Tilatamig Biosimilar is a research-grade therapeutic antibody that specifically targets the tyrosine-protein kinase Met and ERBB1. Its structure, activity, and potential applications make it a promising candidate for the treatment of various types of cancer. Further clinical trials are needed to fully evaluate the efficacy and safety of Tilatamig Biosimilar, but the current data suggests it has the potential to become an important therapeutic option for cancer patients.
ProteoGenix catalogue number PX-TA2218. For research use only.
Target: Tilatamig Biosimilar – Anti-Tyrosine-protein kinase Met;ERBB1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >95% by SDS-PAGE; Buffer: 0.01M PBS, pH 7.4; Applications: Flow Cyt, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Tilatamig Biosimilar – Anti-Tyrosine-protein kinase Met;ERBB1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
